July 31, 2024

HEMGENIX Has Been Administered Across The U.S.

Administered in Green Bay

HEMGENIX is revolutionizing treatment with its groundbreaking one-time infusion that offers elevated and sustained factor IX levels for years. Approved by the FDA in 2022, HEMGENIX has been the focus of extensive research for many years, promising new hope for patients.

We are thrilled to highlight a significant achievement within our team. Andrea Buxton, APNP, one of HOC’s Nurse Practitioners, recently shared her invaluable insights on the preparation and administration experiences for the first two patients to be commercially dosed with HEMGENIX. Her contributions are not only a testament to her expertise but also underscore the innovative spirit that drives our organization.

For more information check out the FAQ’s from HEMGENIX website:

.

 

Recent Posts

Open Enrollment Is Coming: Help Us Keep Your Care on Track

Open enrollment season is approaching, and now is the time to start preparing for any upcoming changes to your health insurance coverage. For many individuals, Medicare Annual Enrollment runs from October 15 through December 7, while Marketplace (ACA) Open Enrollment...

Help Protect Our Community During Virus Season!

Respiratory illnesses such as influenza, COVID-19, and respiratory syncytial virus (RSV) commonly circulate during the colder months, especially as people are spending more times indoors. Symptoms may include fever, cough, sore throat, runny or stuffy nose, fatigue,...

Building Stronger HTCs for Better Patient Care with Angela Blue

Today on Beyond the Bleeds, Heather and guest co-host Erica are joined by Angela Blue, Director of Member & Community Relations with the Hemophilia Alliance, for a conversation about the important work happening behind the scenes to support Hemophilia Treatment...

Social Media